Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection
about
Injecting drug use: A vector for the introduction of new hepatitis C virus genotypesHigh-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methodsMany hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data.Hepatic flares in chronic hepatitis C: spontaneous exacerbation vs hepatotropic viruses superinfection.Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response.Distinct features in natural history and outcomes of acute hepatitis C.Hepatitis C transmission and treatment in contact networks of people who inject drugs.Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infectionLongitudinal Sequence and Functional Evolution within Glycoprotein E2 in Hepatitis C Virus Genotype 3a InfectionCharacterization of Hepatitis C Virus Recombination in Cameroon by Use of Nonspecific Next-Generation Sequencing.Rapid hepatitis C virus divergence among chronically infected individuals.Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccineIncident Hepatitis C Virus Genotype Distribution and Multiple Infection in Australian PrisonsFactors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review.High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study.Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements.HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs.HCV avidity as a tool for detection of recent HCV infection: sensitivity depends on HCV genotype.HCV reinfection incidence among individuals treated for recent infection.Temporal dynamics of hepatitis C genotypes in a five-year hospital-based surveillance in Northern Italy.Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.Amino acid residue-specific neutralization and nonneutralization of hepatitis C virus by monoclonal antibodies to the E2 protein.Next-generation sequencing sheds light on the natural history of hepatitis C infection in patients who fail treatment.T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee.Multiple hepatitis C virus (HCV) reinfections in HIV-positive men who have sex with men: no influence of HCV genotype switch or interleukin-28B genotype on spontaneous clearance.Hepatitis C cross-genotype immunity and implications for vaccine developmentBaseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV.Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.Prevalence of mixed genotype hepatitis C virus infections in the UK as determined by genotype-specific PCR and deep sequencing.Model-based estimation of superinfection prevalence from limited datasets.Acute Hepatitis C Infection: New Approaches to Surveillance, Treatment and Prevention
P2860
Q26781991-F1A2CD3B-0750-4AA2-8340-DD5C0AF10304Q28652352-D098484B-A7C8-4D64-9D70-2ACF6D6C18AFQ30884457-070EB474-842F-46C7-A280-DA20072E9EA8Q33735206-1A157DEE-F65A-440E-B8C9-A17E1DFE79D0Q33821728-A87A09ED-5422-49E7-B62D-68BDB4368866Q33955210-60E4A62C-E889-4F39-8C22-8DF1D114FE0EQ35040866-03373ECE-0420-416E-878C-2F794485E5BCQ35053399-5F4DD1AB-C74A-4AE5-943C-9BC97318B9F4Q35630492-B3F06F47-9D85-4E0B-9D7C-8865A4996EFCQ36066888-D57CDB0A-B6EA-4697-99A1-54209AF700BBQ36558964-035114C4-EBEA-4EA3-BDA4-41B1649924B3Q36717008-D53D1565-D01D-4970-A2F6-B1813A4BF52EQ37040556-12171076-2AE2-4A7B-999E-5972BC527981Q37245420-9853750E-58AB-46D5-8A05-E1803EDE0515Q37288631-70069C20-57AF-4DAB-9FA4-55897CB27A9EQ38381584-ABE59B2C-071E-4B63-BD14-7ADA6B6D2C31Q38407675-C4B13C09-6023-4AA0-BF5A-3973A590EE2EQ38692113-FF39D17B-A424-4376-9BD9-3BE83A250C56Q40069643-425F0B24-A74F-4269-A4FC-CEAA5FD54B7DQ40393982-87ABAE23-0E7E-44EE-8E21-B3A4B1968F09Q40611739-097F3485-A7DE-4E32-A145-F857E9E7BE37Q40931707-98283695-877C-483A-BAF0-89E2069B8EF9Q41168118-F69ED3A0-A31D-466C-8B55-0F646F7C9C41Q41940972-DDB40C2D-8AFD-498A-9ABA-27FCFC31916CQ42061089-F512A595-9DD3-45AB-ACC9-2C2E5AC3C0B2Q42226574-F70EE22D-7AA8-4624-ADD8-630C069511A1Q42364607-E341F643-225F-44AC-8921-A0DBA30228C5Q42985117-B9365CF3-D68F-46C4-A29A-DC407E196F3AQ45353791-CA28DB36-F192-4D42-9E32-0F50CB315E4FQ47560950-DC1EB8BA-04D4-4957-B455-C61453932688Q50533686-A804C661-4EF1-4DE5-B85B-A1F6CBA9268CQ58641902-5CA3E27E-3283-46AE-872E-04B251407E26
P2860
Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Hepatitis C virus reinfection ...... icipants with recent infection
@ast
Hepatitis C virus reinfection ...... icipants with recent infection
@en
type
label
Hepatitis C virus reinfection ...... icipants with recent infection
@ast
Hepatitis C virus reinfection ...... icipants with recent infection
@en
prefLabel
Hepatitis C virus reinfection ...... icipants with recent infection
@ast
Hepatitis C virus reinfection ...... icipants with recent infection
@en
P2093
P2860
P50
P356
P1433
P1476
Hepatitis C virus reinfection ...... icipants with recent infection
@en
P2093
ATAHC Study Group
Barbara Yeung
Gail V Matthews
Gregory J Dore
Jason Grebely
John Kaldor
Kathy Petoumenos
Margaret Hellard
P2860
P304
P356
10.1002/HEP.24754
P407
P577
2012-02-29T00:00:00Z